Our first presenter, Dr. John McKinnon, will be presenting on:
CLINICAL IMPACT OF MISSING CMV VIREMIA IN HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS
Human cytomegalovirus (CMV) infection is prevalent in transplant patients, and is frequently associated with significant morbidity and mortality. In CMV positive recipients of allogeneic human stem cell transplantation, the incidence of viral reactivation can be seen in up to 80% of patients, with up to 30% of these patients ultimately developing clinically significant CMV disease.1 The potential clinical impact of missing CMV viremia cannot be understated. In the first part of this presentation, Dr. John McKinnon will present data from his study comparing two commercial assays for the quantitation of CMV and potential relationship with mutations on UL54.
Our second presenter, Dr. Frederick (Rick) Nolte, will be presenting on:
STREAMLINING AND STANDARDIZING MOLECULAR TESTING THROUGH CONSOLIDATION
Consolidation of laboratory testing on a single automated molecular platform can result in many benefits to the laboratory, namely by reducing the number of redundant instruments, streamlining operations, and standardizing testing – all of which may translate into considerable cost savings and improved operational efficiency. In the second part of this presentation, Dr. Rick Nolte presents his experience with consolidating IVDs and LDTs on a versatile molecular platform.
1 J.E. McKinnon et al. Comparison of Roche and Abbott Cytomegalovirus Quantitative PCR Assays in Allogeneic Hematopoietic Cell Transplant Recipients. Poster presented at IDWeek, October 4-8, 2017, San Diego, CA